The global activated clotting time testing market size was estimated at USD 1.19 billion in 2025 and is projected to reach USD 2.13 billion by 2033, growing at a CAGR of 7.6% from 2026 to 2033. The growth of the market is driven by the increasing cardiovascular disease prevalence, growing adoption of point of care diagnostics, and a steady increase in the number of surgical procedures particularly minimally invasive surgeries.
In addition, the expanding use of dialysis and extracorporeal membrane oxygenation (ECMO) procedures is contributing to sustained market demand. Activated Clotting Time (ACT) testing is extensively used across hospitals, cardiac catheterization laboratories, and critical care units to enable real-time monitoring of anticoagulation during complex procedures. Clinical data suggests that ACT tests are frequently performed in operating rooms during cardiac surgeries (32.4%) and cardiac catheterization procedures (32.3%), highlighting its strong and widespread clinical adoption.
The rising global burden of cardiovascular diseases, including coronary artery disease, myocardial infarction, and thrombosis, is a key driver of growth in the ACT testing market. These conditions frequently require surgical and interventional procedures such as cardiac catheterization, angioplasty, and cardiopulmonary bypass, where effective anticoagulation management is critical. During these procedures, patients are administered high doses of anticoagulants, particularly heparin, to prevent thrombus formation within blood vessels and medical devices. However, maintaining the optimal balance of anticoagulation is essential, as excessive dosing can lead to severe bleeding complications. As a result, ACT testing is widely utilized to provide a rapid, real-time assessment of clotting time, enabling clinicians to monitor and adjust anticoagulation therapy effectively.
With the increasing prevalence of cardiovascular diseases globally, there has been a corresponding rise in the volume of cardiac surgeries and interventional procedures. This trend is directly driving demand for ACT testing devices and consumables across hospitals and cardiac catheterization laboratories. For instance, according to the World Health Organization (WHO), global cardiovascular disease cases increased from approximately 311 million in 1990 to around 626 million in 2023, resulting in nearly 19.8 million deaths annually. This increasing disease burden continues to strengthen the need for reliable anticoagulation monitoring solutions, thereby supporting sustained growth in the ACT testing market.
The growing adoption of point-of-care (POC) diagnostics is a key factor driving the market, as it enables rapid bedside testing and faster clinical decision-making. POC ACT testing allows real-time monitoring of anticoagulation during procedures such as surgeries, dialysis, and ECMO, enabling clinicians promptly adjust anticoagulant dosing and reduce the risk of bleeding or clotting complications. Its ability to improve workflow efficiency, minimize sample transport, and support minimally invasive procedures has further accelerated its use. As healthcare systems increasingly shift toward decentralized diagnostics, demand for portable and automated ACT testing devices continues to rise, supported by the growing adoption of advanced systems such as the i-STAT platform in operating room settings.
This product will be delivered within 1-3 business days.
In addition, the expanding use of dialysis and extracorporeal membrane oxygenation (ECMO) procedures is contributing to sustained market demand. Activated Clotting Time (ACT) testing is extensively used across hospitals, cardiac catheterization laboratories, and critical care units to enable real-time monitoring of anticoagulation during complex procedures. Clinical data suggests that ACT tests are frequently performed in operating rooms during cardiac surgeries (32.4%) and cardiac catheterization procedures (32.3%), highlighting its strong and widespread clinical adoption.
The rising global burden of cardiovascular diseases, including coronary artery disease, myocardial infarction, and thrombosis, is a key driver of growth in the ACT testing market. These conditions frequently require surgical and interventional procedures such as cardiac catheterization, angioplasty, and cardiopulmonary bypass, where effective anticoagulation management is critical. During these procedures, patients are administered high doses of anticoagulants, particularly heparin, to prevent thrombus formation within blood vessels and medical devices. However, maintaining the optimal balance of anticoagulation is essential, as excessive dosing can lead to severe bleeding complications. As a result, ACT testing is widely utilized to provide a rapid, real-time assessment of clotting time, enabling clinicians to monitor and adjust anticoagulation therapy effectively.
With the increasing prevalence of cardiovascular diseases globally, there has been a corresponding rise in the volume of cardiac surgeries and interventional procedures. This trend is directly driving demand for ACT testing devices and consumables across hospitals and cardiac catheterization laboratories. For instance, according to the World Health Organization (WHO), global cardiovascular disease cases increased from approximately 311 million in 1990 to around 626 million in 2023, resulting in nearly 19.8 million deaths annually. This increasing disease burden continues to strengthen the need for reliable anticoagulation monitoring solutions, thereby supporting sustained growth in the ACT testing market.
The growing adoption of point-of-care (POC) diagnostics is a key factor driving the market, as it enables rapid bedside testing and faster clinical decision-making. POC ACT testing allows real-time monitoring of anticoagulation during procedures such as surgeries, dialysis, and ECMO, enabling clinicians promptly adjust anticoagulant dosing and reduce the risk of bleeding or clotting complications. Its ability to improve workflow efficiency, minimize sample transport, and support minimally invasive procedures has further accelerated its use. As healthcare systems increasingly shift toward decentralized diagnostics, demand for portable and automated ACT testing devices continues to rise, supported by the growing adoption of advanced systems such as the i-STAT platform in operating room settings.
Global Activated Clotting Time Testing Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global activated clotting time testing market report on the basis of product, test type, application, end-use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- ACT Analyzers
- Consumables (Cartridges, Tubes, Reagents)
Test Type Outlook (Revenue, USD Million, 2021-2033)
- High-Range ACT Tests
- Low-Range ACT Tests
Application Outlook (Revenue, USD Million, 2021-2033)
- Cardiovascular Surgery
- Interventional Cardiology
- Extracorporeal Membrane Oxygenation (ECMO)
- Hemodialysis
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Hospital
- Ambulatory Surgical Centers
- Clinical Laboratories
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Rest of Middle East & Africa
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Activated Clotting Time Testing Market Variables, Trends & Scope
Chapter 4. Activated Clotting Time Testing Market: Product Estimates & Trend Analysis
Chapter 5. Activated Clotting Time Testing Market: Test Type Estimates & Trend Analysis
Chapter 6. Activated Clotting Time Testing Market: Application Estimates & Trend Analysis
Chapter 7. Activated Clotting Time Testing Market: End Use Estimates & Trend Analysis
Chapter 8. Activated Clotting Time Testing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Werfen
- Medtronic
- Helena Laboratories Corporation
- Abbott
- Sienco, Inc.
- F. Hoffmann-La Roche Ltd
- Sysmex Corporation
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- SEKISUI
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.19 Billion |
| Forecasted Market Value ( USD | $ 2.13 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
